Myocardial InfarctionBP-REACHNCT05937685
Reducing Blood Pressure in Patients With High Cardiovascular Risk
A study testing BP REACH Intervention in people with Myocardial Infarction and Hypertension, run by University of Southern California at 4 sites in United States.
Trial summary
BP-REACH is a study of a team-based (pharmacist and health coach) program for lowering blood pressure for people with a prior stroke or heart attack in the Los Angeles Department of Health Services healthcare system. Read more about this study
- Who is it for?
- Ages 35 years and older
- Conditions the study is for
- Myocardial Infarction, Hypertension, Stroke
- What is being tested?
- BP REACH Intervention
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 546 participants
- Where
- 4 sitesUnited States
- Study dates
- 1 Sep 2023to 30 Oct 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 35 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Patients of LA General Medical Center, Rancho Los Amigos, Olive Medical Center or Harbor-UCLA Medical Center with ischemic stroke, hemorrhagic stroke, or myocardial infarction
- English or Spanish speaking
- Systolic blood pressure (SBP) ≥ 130 mm Hg
Who cannot join
- Age < 35 years
- SBP < 130 mm Hg
- Only speaks a language other than English or Spanish
- Cannot provide informed consent due to dementia or aphasia
Trial locations and contacts
4 sites in 1 country.
United States4 sites
Rancho Los Amigos National Rehabilitation Center
Downey, California, 90242
LA General Medical Center
Los Angeles, California, 90033
Olive View Medical Center
Sylmar, California, 91342
Harbor UCLA Medical Center
Torrance, California, 90502
About this study
Official title: BP-REACH: Blood Pressure Disparities Reduction, Equity, and Access Among Safety Net Patients With Cardiovascular Health Risk
BP-REACH is a study of a team-based (pharmacist and health coach) program for lowering blood pressure for people with a prior stroke or heart attack in the Los Angeles Department of Health Services healthcare system.
The goal of this clinical trial is to test if this team based program is better at helping people reduce their blood pressure than usual care for people with prior heart attack or stroke. The main questions it aims to answer are:
- Do people in the REACH BP program have lower blood pressure at 12 months compared to those getting usual care?
- Do people in the REACH BP program have better Life's Essential 8 scores and patient experience compared to those getting usual care?
Read the detailed description
Hypertension is the leading contributor to preventable death and a major risk factor for recurrent cardiovascular events. To enhance BP control after stroke or myocardial infarction (MI), multilevel interventions are needed that incorporate health system and patient level factors.
BP-REACH aims to test the impact of an intervention on systolic blood pressure (SBP) for individuals with a history of stroke or MI in a randomized controlled trial in the Los Angeles Department of Health Services healthcare system. The primary outcome will be change in systolic blood pressure (SBP) at 12 months.
Hypothesis: Patients randomized to the intervention will achieve >2.4 mm Hg greater reduction in SBP at 1 year versus those randomized to usual care.
The study population will include participants from the inpatient and outpatient settings in Los Angeles County Department of Health Services health centers. The participants will be randomized in a 1:1 fashion to usual care or intervention, stratified by site, language and cardiovascular event (myocardial infarction, stroke). Outcomes will be collected from all participants at Baseline, 3 month and 12 month timepoints. The primary outcome is SBP.
Participants randomized to the intervention arm will receive additional a home blood pressure monitor, monthly phone calls from a health coach, and medication initiation and titration by a clinical pharmacist. The pharmacist will follow Los Angeles County Department of Health Services expected practices, which align with the ACC/AHA guidelines for blood pressure control and AHA guidelines for Secondary Stroke Prevention.
- Conditions
- Myocardial Infarction, Hypertension, Stroke
- Being tested
- BP REACH Intervention
- Keywords
- stroke, myocardial infarction, hypertension, self-management, chronic disease
- Medical subject headings
- Myocardial Infarction, Hypertension, Stroke, Chronic Disease
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
BP REACH InterventionBehavioural
Educational materials, written and digital. Home blood pressure monitor and self management education from BP REACH coach. Monthly coaching calls from BP REACH coach. Medication management by pharmacist
| Study group | Role | What they receive |
|---|---|---|
| Usual Care | No intervention | Participants receive the usual care received by patients of the medical center |
| Intervention | Experimental | Participants follow the intervention protocol, including receiving educational materials, a home blood pressure monitor, coaching calls from BP REACH coaches and medication management from a pharmacist. Receives: Behavioral: BP REACH Intervention |
What is being measured
The primary outcome is the main question the study is designed to answer.
Systolic blood pressure (SBP) mmHG
Collected by study staff using blood pressure monitor
Measured: 12 months
Secondary outcomes (7)
Life's Essential 8
American Heart Association - survey measure. Score of 0-100, with 100 indicating a perfect score for cardiovascular health
Measured: 12 months
BMI (body mass index)
Height (cm) and weight (kg) collected by study staff, height divided by height indicating percentage of fat on the body
Measured: 12 months
Total cholesterol
Lab collection by study staff
Measured: 12 months
HgbA1c (hemoglobin A1C)
Lab collection by study staff
Measured: 12 months
Diet
Survey - California Health Interview Survey
Measured: 12 months
Physical activities
Survey - Behavioral Risk Factor Surveillance System Survey Questionnaire
Measured: 12 months
Smoking
Survey - PATH wave 1 survey
Measured: 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Jul 2023
- Study start1 Sep 2023
- Primary completion30 Oct 2026 (estimated)
- Study completion30 Oct 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Myocardial InfarctionStudies of the same condition, open and under way.
- More trials run by University of Southern CaliforniaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 546 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Southern California
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Amytis Towfighi, University of Southern California
- Investigators
- Alejandra Casillas, MD, Principal investigator, University of California, Los AngelesAmytis Towfighi, MD, Principal investigator, University of Southern California
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05937685
- Sponsor's protocol ID
- 1P50MD017366-01
- Acronym
- BP-REACH
- Status last verified
- Sep 2026
- First submitted
- 30 Jun 2023
- Last updated
- 14 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- BP-REACH: Blood Pressure Disparities Reduction, Equity, and Access Among Safety Net Patients With Cardiovascular Health Risk
- ClinicalTrials.gov ID
- NCT05937685
- Acronym / sponsor ID
- BP-REACH / 1P50MD017366-01
- Conditions
- Myocardial Infarction, Hypertension, Stroke
- Keywords
- stroke, myocardial infarction, hypertension, self-management, chronic disease
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 546 participants (estimated)
- Lead sponsor
- University of Southern CaliforniaUniversity, hospital or other
- Collaborators
- University of California, Los Angeles, University of California, Irvine
- Study start
- 1 Sep 2023 (actual)
- Primary completion
- 30 Oct 2026 (estimated)
- Study completion
- 30 Oct 2026 (estimated)
- First posted
- 10 Jul 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
BP-REACH is a study of a team-based (pharmacist and health coach) program for lowering blood pressure for people with a prior stroke or heart attack in the Los Angeles Department of Health Services healthcare system.
The goal of this clinical trial is to test if this team based program is better at helping people reduce their blood pressure than usual care for people with prior heart attack or stroke. The main questions it aims to answer are:
- Do people in the REACH BP program have lower blood pressure at 12 months compared to those getting usual care?
- Do people in the REACH BP program have better Life's Essential 8 scores and patient experience compared to those getting usual care?
Detailed description
Hypertension is the leading contributor to preventable death and a major risk factor for recurrent cardiovascular events. To enhance BP control after stroke or myocardial infarction (MI), multilevel interventions are needed that incorporate health system and patient level factors.
BP-REACH aims to test the impact of an intervention on systolic blood pressure (SBP) for individuals with a history of stroke or MI in a randomized controlled trial in the Los Angeles Department of Health Services healthcare system. The primary outcome will be change in systolic blood pressure (SBP) at 12 months.
Hypothesis: Patients randomized to the intervention will achieve >2.4 mm Hg greater reduction in SBP at 1 year versus those randomized to usual care.
The study population will include participants from the inpatient and outpatient settings in Los Angeles County Department of Health Services health centers. The participants will be randomized in a 1:1 fashion to usual care or intervention, stratified by site, language and cardiovascular event (myocardial infarction, stroke). Outcomes will be collected from all participants at Baseline, 3 month and 12 month timepoints. The primary outcome is SBP.
Participants randomized to the intervention arm will receive additional a home blood pressure monitor, monthly phone calls from a health coach, and medication initiation and titration by a clinical pharmacist. The pharmacist will follow Los Angeles County Department of Health Services expected practices, which align with the ACC/AHA guidelines for blood pressure control and AHA guidelines for Secondary Stroke Prevention.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Usual Care | No intervention | –Participants receive the usual care received by patients of the medical center |
| Intervention | Experimental | Behavioral: BP REACH InterventionParticipants follow the intervention protocol, including receiving educational materials, a home blood pressure monitor, coaching calls from BP REACH coaches and medication management from a pharmacist. |
Who may qualify
- Ages
- 35 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Patients of LA General Medical Center, Rancho Los Amigos, Olive Medical Center or Harbor-UCLA Medical Center with ischemic stroke, hemorrhagic stroke, or myocardial infarction
- English or Spanish speaking
- Systolic blood pressure (SBP) ≥ 130 mm Hg
Key exclusion criteria (4 listed)
- Age < 35 years
- SBP < 130 mm Hg
- Only speaks a language other than English or Spanish
- Cannot provide informed consent due to dementia or aphasia
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| BP REACH InterventionEducational materials, written and digital. Home blood pressure monitor and self management education from BP REACH coach. Monthly coaching calls from BP REACH coach. Medication management by pharmacist | Behavioural | Intervention |
Primary outcome
Systolic blood pressure (SBP) mmHG
Time frame: 12 months
Collected by study staff using blood pressure monitor
7 secondary outcomes
Life's Essential 8
Time frame: 12 months
BMI (body mass index)
Time frame: 12 months
Total cholesterol
Time frame: 12 months
HgbA1c (hemoglobin A1C)
Time frame: 12 months
Diet
Time frame: 12 months
Physical activities
Time frame: 12 months
Smoking
Time frame: 12 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Sep 2026.
- Individual participant dataSharing planned: No
Related trials for Myocardial Infarction
Recruiting
CT Stress Myocardial Perfusion, Fractional Flow Reserve and Angiography in Patients With Stable Chest Pain Syndromes
Coronary Artery Disease, Chest Syndrome
Enrolling by invitation
The DANE-HEART Trial - Computed Tomography Coronary Angiography for Primary Prevention
Coronary Atherosclerosis and Other Heart Disease, Cardiovascular Diseases
Active, not recruitingPhase 3
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
Primary Prevention of Atherosclerotic Cardiovascular Disease
RecruitingPhase 4
Early Single Antiplatelet Therapy After IVUS-Guided PCI in Acute Coronary Syndrome
Acute Coronary Syndromes, STEMI
Not yet recruitingObservational study
Elicit Drugs in Myocardial Infarction
Young Patients With Acute Myocardial Infarction
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Alejandra Casillas, MD principal investigator
University of California, Los Angeles
Amytis Towfighi, MD principal investigator
University of Southern California
4 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing BP REACH Intervention in people with Myocardial Infarction and Hypertension, run by University of Southern California at 4 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 14 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 4 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Systolic blood pressure (SBP) mmHG (time frame: 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Sep 2026; AzTrials last refreshed its copy on 6 Nov 2026.